Cleaver Leaves, a Colombian cannabis multinational company, is looking to expand its business in the near future and become a key player in the world’s cannabis sector. The multinational has offices in countries like the United States, Canada and Germany and is currently cultivating 15 hectares in Colombia. The company exports its products to different markets where it can legally sell them.
In the midst of the Coronavirus crisis, when industries see a dark outlook, Clever Leaves, a company from Boyacá is keeping its employees. In addition, the company has already secured the money, so that when the COVID-19 pandemic begins to give truce, it will contribute to the pharmaceutical industry.
The multinational Clever Leaves is the first Colombian export company and leader in the production of medical cannabis. The company currently cultivates 15 hectares of cannabis plants under the standards of Good Agricultural and Collection Practices (GACP) in Fisheries (Boyacá).
If you want to know more about the cannabis sector fighting for survival in this difficult period the world is facing because of the coronavirus pandemic, how Clever Leaves is planning ahead in order to become a key export company of medical cannabis and to find out the latest cannabis news, download the Hemp.im mobile application.
The Colombian cannabis company shows a promising future
Cleaver Leaves is a renowned Colombian cannabis company, which is aiming to develop and commercialize high-quality cannabis products. Both the company’s CEO, Kyle Detwiler, and the president, Andrés Fajardo, are working together with local governments to ensure that the company follows all the regulations in the country in order to produce and export its products to its trusted partners.
Andrés Fajardo, president of the company, explained in a press release that “Clever Leaves International Inc., a leading multinational operator (MNO) and licensed producer of pharmaceutical-grade medical cannabis and hemp extracts, has already raised $14 million at the close of the first round of “Series E” funding, bringing the Company’s total funding to $120 million.
Currently, Clever Leaves has offices in key countries like the United States, Canada, Germany, and Portugal. That allows the company to develop great partnerships with the biggest cannabis players both in America and Europe. In addition, it assures that the company’s products will be distributed in the most important cannabis markets.
Cowen Inc. acted as exclusive placement agent for the financing. The majority of the capital raised in this round was received from institutional investors with a proven track record in the industry. He added that this is good news, in the midst of the financial crisis brought on by the current coronavirus pandemic.
The future of Clever Leaves in the world cannabis landscape
“Receiving such strong support at this time further validates Clever Leaves’ strategy. This funding demonstrates Clever Leaves’ ability to meet the challenges of the marketplace in these difficult times and will help us achieve our goal of transforming the international cannabis supply chain. The funding will allow us to continue marketing the world-class products produced by our growing and extraction operations in Colombia, as well as complete the licensing process in Portugal,” said Fajardo.
Clever Leaves anticipates raising additional capital in the coming months and expects to use the proceeds primarily to further develop the company’s existing brands and expand its operations in Portugal.
The funds will additionally support the expansion of the company’s recently launched direct sales platform, “Clever Leaves 360”, which offers pharmaceutical-grade cannabis extracts and finished products suitable for a wide range of industries.
The proceeds of the financing may also be used to further enhance the Clever Leaves’ operations in Colombia and to continue expanding distribution channels in Germany and throughout Europe.
As a result, pharmaceutical grade Cannabis Raw Materials and Finished Products are secured for when the world economy begins to normalize.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Caracol, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.